Institute of Biomedicine, University of Turku, Turku, Finland.
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Emerg Microbes Infect. 2022 Dec;11(1):956-963. doi: 10.1080/22221751.2022.2053364.
Pertussis incidence has increased in many countries and the disease occurs among all age groups, suggesting the need for booster immunizations through life. In addition to determining the concentration of anti-pertussis toxin (PT) antibodies, the ability of PT neutralizing antibodies (PTNAs) could be used to assess vaccine responses.Altogether 258 participants [7-10-year-old (N = 73), 11-15-year-old (N = 85), 20-35-year-old (N = 50) and 60-70-year-old (N = 50)] were included. Sera were collected before, one month, and one year after a single dose of a three pertussis component containing acellular pertussis vaccine. The adolescents were primed in childhood either by acellular or whole-cell vaccination. PTNA titres were determined by a Chinese hamster ovary cell assay and anti-PT IgG/IgA antibody concentrations by multiplex immunoassay.In all age groups, a significant increase in levels of PTNAs and anti-PT IgG was observed one month after vaccination and remained at least two-fold higher one year post-booster, in comparison to pre-booster. Young adults had the lowest response. The strongest increase in PTNAs was observed in participants who had ≥10 IU/mL concentration of anti-PT IgG antibodies pre-booster. At pre-booster, whole-cell-primed adolescents had higher PTNAs than acellular-primed peers ( = 0.047). One year post-booster, the Finnish whole-cell-primed adolescents had a higher level of PTNAs than acellular-primed adolescents ( = 0.049), however, this was not observed in Dutch adolescents. In conclusion, PTNAs increased after vaccination in all age groups, and the strongest increase was related to the presence of high pre-booster antibodies.
百日咳发病率在许多国家都有所增加，并且该病发生在所有年龄段，这表明需要终生加强免疫接种。除了确定抗百日咳毒素 (PT) 抗体的浓度外，PT 中和抗体 (PTNAs) 的能力可用于评估疫苗反应。共有 258 名参与者[7-10 岁（N=73）、11-15 岁（N=85）、20-35 岁（N=50）和 60-70 岁（N=50）]被纳入研究。所有参与者均在单次接种三组分无细胞百日咳疫苗一个月前、一个月后和一年后采集血清。青少年在儿童期通过无细胞或全细胞疫苗进行了初免。通过中国仓鼠卵巢细胞测定法测定 PTNAs 滴度，通过多重免疫测定法测定抗-PT IgG/IgA 抗体浓度。在所有年龄组中，与加强接种前相比，接种一个月后 PTNAs 和抗-PT IgG 水平显著升高，且至少在加强接种后一年保持两倍以上。年轻成年人的反应最低。在加强接种前具有≥10 IU/mL 抗-PT IgG 抗体浓度的参与者中，观察到 PTNAs 最强的增加。在加强接种前，全细胞初免的青少年的 PTNAs 高于无细胞初免的同龄人（=0.047）。加强接种一年后，芬兰全细胞初免的青少年的 PTNAs 水平高于无细胞初免的青少年（=0.049），但荷兰青少年未观察到这种情况。总之，所有年龄组在接种后 PTNAs 均增加，且最强的增加与加强接种前高抗体的存在有关。
